<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01374802</url>
  </required_header>
  <id_info>
    <org_study_id>1220.49</org_study_id>
    <secondary_id>2011-000505-41</secondary_id>
    <nct_id>NCT01374802</nct_id>
  </id_info>
  <brief_title>Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female Volunteers</brief_title>
  <official_title>Effect of Multiple Dosing With 240 mg QD BI 201335 on the Steady-state Pharmacokinetics of 800 mg QD Darunavir Coadministered With 100 mg QD Ritonavir (DRV/r) in Healthy Male and Female Volunteers (an Open-label, Multiple-dose, Single Group, Single Fixed Sequence Phase I Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the current study is to investigate the effect of multiple oral daily doses
      of BI 201335 on the steady-state pharmacokinetics of darunavir co-administered with
      ritonavir.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ,ss of Darunavir</measure>
    <time_frame>0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 hours (h) after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)</time_frame>
    <description>area under the concentration-time curve of the analyte in plasma at steadystate over a uniform dosing interval τ of darunavir.
The measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cτ,ss of Darunavir</measure>
    <time_frame>0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 h after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)</time_frame>
    <description>concentration of the analyte in plasma at steady-state after a uniform dosing interval τ=24h of darunavir</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss of Darunavir</measure>
    <time_frame>0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 h after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)</time_frame>
    <description>maximum measured concentration of the analyte in plasma at steady-state</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss of Darunavir</measure>
    <time_frame>0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 hours (h) after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)</time_frame>
    <description>time from last dosing to maximum concentration of the analyte in plasma at steady state</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>BI 201335</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capsule for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Darunavir 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablet for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ritonavir 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablet for oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>400 mg tablet for oral administration</description>
    <arm_group_label>Darunavir 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>tablet for oral administration</description>
    <arm_group_label>Ritonavir 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335</intervention_name>
    <arm_group_label>BI 201335</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy male and female subjects according to the following criteria: medical history,
             physical examination, vital signs (blood pressure, pulse rate), 12-lead
             electrocardiogram (ECG), clinical laboratory tests

          2. Age 18 to 55 years (incl.)

          3. Body Mass Index (BMI) 18.5 to 29.9 kg/m2 (incl.) and weight greater than 50 kg

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice (GCP) and the local legislation.

        Exclusion criteria:

          1. Any finding of the medical examination (including blood pressure (BP), pulse rate (PR)
             and ECG) deviating from normal and of clinical relevance

          2. Any evidence of a clinically relevant concomitant disease

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          4. History of photosensitivity or recurrent rash.

          5. Surgery of the gastrointestinal tract (except appendectomy)

          6. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          7. History of relevant orthostatic hypotension, fainting spells or blackouts.

          8. Chronic or relevant acute infections

          9. History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients)

         10. Intake of drugs with a long half-life (more than 24 hours) within at least one month
             or less than 10 half-lives of the respective drug prior to administration or during
             the trial

         11. Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

         12. Smoker (more than 10 cigarettes)

         13. Inability to refrain from smoking on trial days

         14. Alcohol abuse (more than 30 g/day)

         15. Drug abuse

         16. Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial)

         17. ALT outside the normal range or any other laboratory value outside the reference range
             that is of clinical relevance

         18. Inability to comply with dietary regimen of trial site

         19. The subject is not able to understand and comply with protocol requirements,
             instructions and protocol-stated restrictions

         20. Positive serology tests for Human immunodeficiency virus (HIV) and hepatitis B / C
             virus

         21. Vulnerable subjects (e.g. persons kept in detention)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1220.49.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2011</study_first_submitted>
  <study_first_submitted_qc>June 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2011</study_first_posted>
  <results_first_submitted>July 3, 2015</results_first_submitted>
  <results_first_submitted_qc>July 3, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 31, 2015</results_first_posted>
  <last_update_submitted>July 3, 2015</last_update_submitted>
  <last_update_submitted_qc>July 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Subjects</title>
          <description>The study was performed as an open-label, multiple-dose, single-group, fixed-sequence study in 14 healthy volunteers.
Period 1: Darunavir 800 mg once daily coadministered with ritonavir 100 mg (DRV/r).
Period 2: Faldaprevir together with DRV/r.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The study was performed as an open-label, multiple-dose, single-group, fixed-sequence study in 14 healthy volunteers.</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>The study was performed as an open-label, multiple-dose, single-group, fixed-sequence study in 14 healthy volunteers.
Period 1: darunavir 800 mg once daily coadministered with ritonavir 100 mg (DRV/r).
Period 2: faldaprevir together with DRV/r.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.4" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUCτ,ss of Darunavir</title>
        <description>area under the concentration-time curve of the analyte in plasma at steadystate over a uniform dosing interval τ of darunavir.
The measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities</description>
        <time_frame>0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 hours (h) after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)</time_frame>
        <population>Pharmacokinetic (PK) set: all subjects in the treated set who provided at least one observation for at least one primary endpoint without any important protocol violations relevant to the pharmacokinetic evaluation and who did not experience vomiting at or before 2 times median tmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Darunavir+Ritonavir</title>
            <description>oral administration of darunavir 800 mg once daily coadministered with ritonavir 100 mg (DRV/r) once daily</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir+Darunavir+Ritonavir</title>
            <description>oral administration of Faldaprevir 240 mg once daily together with DRV/r. Faldaprevir 480 mg loading dose together with DRV/r on the first day.</description>
          </group>
        </group_list>
        <measure>
          <title>AUCτ,ss of Darunavir</title>
          <description>area under the concentration-time curve of the analyte in plasma at steadystate over a uniform dosing interval τ of darunavir.
The measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities</description>
          <population>Pharmacokinetic (PK) set: all subjects in the treated set who provided at least one observation for at least one primary endpoint without any important protocol violations relevant to the pharmacokinetic evaluation and who did not experience vomiting at or before 2 times median tmax.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57200" spread="29.5"/>
                    <measurement group_id="O2" value="66000" spread="39.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison (Faldaprevir+DRV/r : DRV/r) of Darunavir</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>115.29</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>19.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>101.36</ci_lower_limit>
            <ci_upper_limit>131.13</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cτ,ss of Darunavir</title>
        <description>concentration of the analyte in plasma at steady-state after a uniform dosing interval τ=24h of darunavir</description>
        <time_frame>0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 h after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Darunavir+Ritonavir</title>
            <description>oral administration of darunavir 800 mg once daily coadministered with ritonavir 100 mg (DRV/r) once daily</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir+Darunavir+Ritonavir</title>
            <description>oral administration of Faldaprevir 240 mg once daily together with DRV/r. Faldaprevir 480 mg loading dose together with DRV/r on the first day.</description>
          </group>
        </group_list>
        <measure>
          <title>Cτ,ss of Darunavir</title>
          <description>concentration of the analyte in plasma at steady-state after a uniform dosing interval τ=24h of darunavir</description>
          <population>PK set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1330" spread="49.5"/>
                    <measurement group_id="O2" value="1170" spread="90.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison (Faldaprevir+DRV/r : DRV/r) of Darunavir</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>87.91</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>38.3</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>68.609</ci_lower_limit>
            <ci_upper_limit>112.630</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax,ss of Darunavir</title>
        <description>maximum measured concentration of the analyte in plasma at steady-state</description>
        <time_frame>0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 h after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Darunavir+Ritonavir</title>
            <description>oral administration of darunavir 800 mg once daily coadministered with ritonavir 100 mg (DRV/r) once daily</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir+Darunavir+Ritonavir</title>
            <description>oral administration of Faldaprevir 240 mg once daily together with DRV/r. Faldaprevir 480 mg loading dose together with DRV/r on the first day.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax,ss of Darunavir</title>
          <description>maximum measured concentration of the analyte in plasma at steady-state</description>
          <population>PK set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4930" spread="23.9"/>
                    <measurement group_id="O2" value="6330" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison (Faldaprevir+DRV/r : DRV/r) of Darunavir</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>128.41</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>15.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>115.724</ci_lower_limit>
            <ci_upper_limit>142.489</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax,ss of Darunavir</title>
        <description>time from last dosing to maximum concentration of the analyte in plasma at steady state</description>
        <time_frame>0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 hours (h) after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Darunavir+Ritonavir</title>
            <description>oral administration of darunavir 800 mg once daily coadministered with ritonavir 100 mg (DRV/r) once daily</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir+Darunavir+Ritonavir</title>
            <description>oral administration of Faldaprevir 240 mg once daily together with DRV/r. Faldaprevir 480 mg loading dose together with DRV/r on the first day.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax,ss of Darunavir</title>
          <description>time from last dosing to maximum concentration of the analyte in plasma at steady state</description>
          <population>PK set</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="33.9" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="2.01" spread="37.3" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) occurring up to 9 days after first drug administration of DRV/r were assigned to the treatment DRV/r and AEs occurring up to 13 days after last drug administration of DRV/r+FDV were assigned to the combined treatment DRV/r+FDV.</time_frame>
      <desc>The subjects were required to spontaneously report any AEs. In addition, subjects were assessed regularly for AEs during the trial.</desc>
      <group_list>
        <group group_id="E1">
          <title>Darunavir+Ritonavir</title>
          <description>oral administration of darunavir 800 mg once daily coadministered with ritonavir 100 mg (DRV/r)once daily</description>
        </group>
        <group group_id="E2">
          <title>Faldaprevir+Darunavir+Ritonavir</title>
          <description>oral administration of Faldaprevir 240 mg once daily together with DRV/r. Faldaprevir 480 mg loading dose together with DRV/r on the first day.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

